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Metastases status

List S1: EURAMOS-1 Investigators And Participants
EURAMOS
Oncology Panel
The oncology panels of each group checked the protocol for content, consistency and accuracy on all topics surrounding study medication. Members of each group's oncology panel were appointed to represent the group in the TMG and the TSC. Some groups offered or required consultation with named members of the oncology panel on issues surrounding chemotherapy.
Pathology review panel
The purpose of the Pathology Review Panel was to ensure that the histopathological criteria for admission to the trial and histological response to chemotherapy were assessed in a timely and consistent fashion for all trial groups participating in EURAMOS 1. Each of the participating groups formed a pathology sub-panel. Together, these form the pathology panel of the EURAMOS 1 trial. Each of the 4 collaborating groups named one representative pathologist to represent their group in intergroup discussions. These four elected one pathologist to represent pathology in the Trial Management Committee.
Pathology review was to be undertaken for all patients within the trial. Both the diagnostic biopsy and the resection specimen histology were to be reviewed by a study pathologist. The process of pathology review is detailed in the protocol.
Biological Studies panel
Parallel biological studies were performed in selected groups for this trial lead by the biological studies panel.
The biological studies panel were responsible for the development of protocols within their trial group and for ensuring the use of uniform methodologies between groups to allow data comparability.
Surgical panel
The surgical panel issued guidance surrounding tumour resection and reconstruction. Some groups offered or required consultation with members of the surgical panel prior to tumour surgery.
Radiology panel
The radiology panel issued guidance surrounding imaging of the primary tumour and of metastatic disease. Members of the panel assisted in determining metastatic status. Review of thorax CT scans was undertaken by members of the trial management group in conjunction with a panel radiologist. Central review of chest CT scans was requested for patients registered as having (possible) metastatic disease and fulfilling the following criteria: no lesion greater than 1 cm or less than 3 lesions of any size.
Radiotherapy panel
The radiotherapy panel issued guidance surrounding radiotherapy for insufficient margins or inoperable relapse. Some groups offered or required consultation with members of the radiotherapy panel prior to irradiating a specific patient.
Statistics panel
The statistics panel was involved in all aspects of trial design, data storage and management, and evaluation.
